Regulatory T cells: Potential target in anticancer immunotherapy

Taiwanese Journal of Obstetrics and Gynecology

Volumn 46, Issue 3, 2007, Pages 215-221

  Juang, Chi Mou ^a,b,c   Hung, Chien Fu ^c   Yeh, Jiun Yih ^a   Horng, Huann Cheng ^a   Twu, Nae Fong ^a   Cheng, Ming Huei ^a   Wen, Kuo Chang ^a   Yuan, Chiou Chung ^a   Chao, Kuan Chong ^a   Wu, T C ^c   Yen, Ming Shien ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

CD25; Foxp3; Immunotherapy; Regulatory T cells

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA;

AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREGNANCY; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RESEARCH; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 35348827410     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60023-6     Document Type: Review

References (63)

1. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
3. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609-14.
4. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996;19:81-4.
5. Berendt MJ, North RJ. T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980;151:69-80.
6. North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res 1985;45:1-43.
7. Mukherji B, Wilhelm SA, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 1986;136:1888-92.
8. Mukherji B, Nashed AL, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression J Immunol 1986;136:1893-8.
9. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 1989;169:1961-76.
10. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
11. Sakaguchi N, Miyai K, Sakaguchi S. Ionizing radiation and autoimmunity. Induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J Immunol 1994;152:2586-95.
12. + regulatory cells as a potential immunotherapy. Philos Trans R Soc Lond B Biol Sci 2005;360:1647-61.
13. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005;54:1153-61.
14. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005;4:351-63.
15. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
16. high regulatory T cells in human pregnancy. J Reprod Immunol 2005;65:111-20.
17. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253-7.
18. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985;161:72-87.
19. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-71.
20. + CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
21. + T cell numbers. J Immunol 2002;169:4850-60.
22. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201:723-35.
23. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
24. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-10.
25. + as well as CD25- regulatory T cells. Proc Natl Acad Sci U S A 2002;99:13031-6.
26. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311-23.
27. + regulatory T cells. Semin Immunol 2004;16:89-98.
28. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003;33:215-23.
29. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001;31:1122-31.
30. + T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 2000;164:240-7.
31. + regulatory T cells in human thymus. Nature 2005;436:1181-5.
32. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004;199:1401-8.
33. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
34. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-44.
35. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol 2002;169:6210-7.
36. Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-302.
37. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-44.
38. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999;48:353-62.
39. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998;4:63-8.
40. Ganss R, Arnold B, Hammerling GJ. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 2004;34:2635-41.
41. + regulatory T cells in normal and tumor-bearing mice. Int Immunopharmacol 2004;4:1785-93.
42. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
43. Takahashi T, Sakaguchi S. The role of regulatory T cells in controlling immunologic self-tolerance. Int Rev Cytol 2003;225:1-32.
44. + regulatory T cells. J Exp Med 2005;202:885-91.
45. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-33.
46. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
47. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005;92:913-20.
48. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
49. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
50. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
51. Gray CP, Arosio P, Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 2002;99:3326-34.
52. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
53. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-32.
54. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
55. Baecher-Allan C, Anderson DE. Immune regulation in tumor-bearing hosts. Curr Opin Immunol 2006;18:214-9.
56. Needham DJ, Lee JX, Beilharz MW. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006;343:684-91.
57. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 2005;23:662-4.
58. + suppressor T-cells. Cancer Res 1989;49:1649-54.
59. + regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 2005;16:1360-70.
60. Kuzel TM. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date. Clin Lymphoma 2000;1(Suppl 1):S33-6.
61. + regulatory T cell function. Science 2005;309:1380-4.
62. Zhou X, Zheng L, Liu L, Xiang L, Yuan Z. T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides. Scand J Immunol 2003;58:350-7.
63. Zhou X, Xie Y, Tao X, Zhang Z, Li Z, Fauquet CM. Characterization of DNAbeta associated with begomoviruses in China and evidence for co-evolution with their cognate viral DNA-A. J Gen Virol 2003;84:237-47.